Kyverna Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview

Kyverna Therapeutics

08/08/2025 23:36

Kyverna Therapeutics Inc KYTX.OQ KYTX.O is expected to  show no change in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

‚ÄãLSEG's mean analyst estimate for Kyverna Therapeutics Inc is for a loss of $1.04 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äã

Wall Street's median 12-month price target for Kyverna Therapeutics Inc is $20.00, about 83.8% above its last closing price of $3.24

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äã

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.18
-1.11
-1.03
Beat
7.5
Dec. 31 2025
-0.84
-0.88
Missed
-5
Sep. 30 2024
-0.79
-0.79
-0.80
Missed
-1.5‚Äã
Jun. 30 2024
-0.69
-0.70
-0.67
Beat
4
‚Äã‚ÄãMar. 31 2024
-0.96
-0.84
-1.12
Missed
-33.3
Dec. 31 2023
-3.23
-3.23
-26.86
Missed
-732.4‚Äã

This summary was machine generated August 8 at 22:36 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)